We are determined to help as many people as possible in a way that is rigorous and collaborative.
Our approach to scientific innovation
From advancing our investigational COMP360 psilocybin therapy for treatment-resistant depression, to building new care models, we will work with all parts of the healthcare system to develop scalable, evidence-based innovation to improve mental health care outcomes in all parts of our society.
Our commitment to Open Science
We are fully committed to Open Science. We will publish the results from all our trials and we support the publication of all results from independent studies that use our proprietary formulation of synthetic psilocybin, COMP360. Read more about our approach here
Learn more about our rigorous and collaborative approach to research
Accelerating mental health research in collaboration with One Mind
We're collaborating with One Mind to sponsor three One Mind Rising Star Awards.
COMPASS recently conducted a survey with Sermo, a global leader in physician insights, to discover how psychiatrists view the potential future role of psilocybin therapy in treating mental health illnesses, such as treatment-resistant depression.
Our Centres of Excellence
In January 2021, we established our first Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care.
Our Discovery Center
Our Discovery Center focuses on developing optimized psychedelic and related compounds targeting the 5-HT2A receptor.
We have provided support, training and funding for the investigator-initiated study using our COMP360 psilocybin therapy in cancer patients with depression at The Aquilino Cancer Center.
Global research partnerships
We work with the Psychiatry Consortium, an international collaboration to accelerate drug discovery and development in areas of urgent, unmet medical need.
As part of our commitment to animal welfare, we have joined the Concordat on Openness on Animal Research in the UK.